BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SER-252 (PEOZ-apomorphine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SER-252 (PEOZ-apomorphine)\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07422675-1716@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:SER-252 (PEOZ-apomorphine): Phase 1 readout est. (NCT07422675)
DESCRIPTION:SER-252 (PEOZ-apomorphine)\, phase 1\, Parkinson's Disease.\nSt
 udy: SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
 \nEstimated primary completion: 31 January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ser-252-peoz-apomorphine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07422675
URL:https://assetmemo.bio/drug/ser-252-peoz-apomorphine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
